ArticleTurk gogus kalp damar cerrahisi dergisi2025
Optimized retrograde approach and device selection with Konar-MF™ for pediatric transcatheter ventricular septal defect closure.
Article in Turk gogus kalp damar cerrahisi dergisi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of KONAR-multifunctional occluder and Amplatzer occluders in transcatheter closure of patent arterial ducts and ventricular septal defects.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Transcatheter ventricular septal defect closure in children: ten-year experience with multiple devices and long-term outcomes.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Multiple Mitral Paravalvular Leak Closure With VSD Occluder in a High Surgical Risk Patient.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to evaluate the mid-term outcomes of transcatheter ventricular septal defect closure with the Konar-MF™ device and to investigate the impact of an optimized device selection strategy using a retrograde approach. Methods: Between January 2019 and November 2023, a total of 58 patients (32 males, 26 females; median age: 4.5 years; range, 8 months to 16 years) who underwent transcatheter closure of ventricular septal defects using the Konar-MF™ device were retrospectively analyzed. Patient demographics, procedural details, and follow-up data were recorded. Results: Procedural success was achieved in 95% of cases, with a median procedure time of 60 min and fluoroscopy time of 12.6 min. Retrograde implantation was used in 79% of patients, significantly reducing procedural time and minimizing complications associated with an arteriovenous loop. Our refined strategy of selecting smaller devices when anatomically feasible played a crucial role in reducing interference with surrounding cardiac structures, substantially contributing to the absence of complete atrioventricular block in our cohort. Major complications included device embolization, moderate aortic regurgitation due to device dislocation, and right ventricular perforation (each in 1.8% of patients). The median follow-up was 34.5 months. Residual shunt rates were initially 42% on postoperative Day 1, reducing to 1.8% by the end of the follow-up period. Conclusion: The Konar-MF™ occluder demonstrated high procedural success and acceptable complication rates for perimembranous ventricular septal defect closure. The use of a retrograde approach and a refined device selection strategy were key factors in achieving favorable outcomes, minimizing complications such as atrioventricular block and valve interference. The device offers significant advantages, making it a suitable alternative to surgical ventricular septal defect closure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.